Literature DB >> 23917318

Mechanism of action of T-705 ribosyl triphosphate against influenza virus RNA polymerase.

Hidehiro Sangawa1, Takashi Komeno, Hiroshi Nishikawa, Atsushi Yoshida, Kazumi Takahashi, Nobuhiko Nomura, Yousuke Furuta.   

Abstract

T-705 (favipiravir; 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) selectively and strongly inhibits replication of the influenza virus in vitro and in vivo. T-705 has been shown to be converted to T-705-4-ribofuranosyl-5-triphosphate (T-705RTP) by intracellular enzymes and then functions as a nucleotide analog to selectively inhibit RNA-dependent RNA polymerase (RdRp) of the influenza virus. To elucidate these inhibitory mechanisms, we analyzed the enzyme kinetics of inhibition using Lineweaver-Burk plots of four natural nucleoside triphosphates and conducted polyacrylamide gel electrophoresis of the primer extension products initiated from (32)P-radiolabeled 5'Cap1 RNA. Enzyme kinetic analysis demonstrated that T-705RTP inhibited the incorporation of ATP and GTP in a competitive manner, which suggests that T-705RTP is recognized as a purine nucleotide by influenza virus RdRp and inhibited the incorporation of UTP and CTP in noncompetitive and mixed-type manners, respectively. Primer extension analysis demonstrated that a single molecule of T-705RTP was incorporated into the nascent RNA strand of the influenza virus and inhibited the subsequent incorporation of nucleotides. These results suggest that a single molecule of T-705RTP is incorporated into the nascent RNA strand as a purine nucleotide analog and inhibits strand extension, even though the natural ribose of T-705RTP has a 3'-OH group, which is essential for forming a covalent bond with the phosphate group.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23917318      PMCID: PMC3811313          DOI: 10.1128/AAC.00649-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  25 in total

1.  Proofreading function associated with the RNA-dependent RNA polymerase from influenza virus.

Authors:  A Ishihama; K Mizumoto; K Kawakami; A Kato; A Honda
Journal:  J Biol Chem       Date:  1986-08-05       Impact factor: 5.157

Review 2.  Ribavirin's antiviral mechanism of action: lethal mutagenesis?

Authors:  Shane Crotty; Craig Cameron; Raul Andino
Journal:  J Mol Med (Berl)       Date:  2001-12-04       Impact factor: 4.599

3.  The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen.

Authors:  S Crotty; D Maag; J J Arnold; W Zhong; J Y Lau; Z Hong; R Andino; C E Cameron
Journal:  Nat Med       Date:  2000-12       Impact factor: 53.440

4.  Characterization of influenza virus RNA complete transcripts.

Authors:  A J Hay; J J Skehel; J McCauley
Journal:  Virology       Date:  1982-01-30       Impact factor: 3.616

5.  In vitro and in vivo activities of anti-influenza virus compound T-705.

Authors:  Y Furuta; K Takahashi; Y Fukuda; M Kuno; T Kamiyama; K Kozaki; N Nomura; H Egawa; S Minami; Y Watanabe; H Narita; K Shiraki
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

6.  Acyclic guanosine analogs inhibit DNA polymerases alpha, delta, and epsilon with very different potencies and have unique mechanisms of action.

Authors:  D D Ilsley; S H Lee; W H Miller; R D Kuchta
Journal:  Biochemistry       Date:  1995-02-28       Impact factor: 3.162

7.  Recombinant influenza virus polymerase: requirement of both 5' and 3' viral ends for endonuclease activity.

Authors:  M Hagen; T D Chung; J A Butcher; M Krystal
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

8.  High frequency of resistant viruses harboring different mutations in amantadine-treated children with influenza.

Authors:  Kyoko Shiraishi; Keiko Mitamura; Yuko Sakai-Tagawa; Hideo Goto; Norio Sugaya; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

9.  Biochemical studies on capped RNA primers identify a class of oligonucleotide inhibitors of the influenza virus RNA polymerase.

Authors:  T D Chung; C Cianci; M Hagen; B Terry; J T Matthews; M Krystal; R J Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

10.  In vitro and in vivo activities of T-705 and oseltamivir against influenza virus.

Authors:  Kazumi Takahashi; Yousuke Furuta; Yoshiko Fukuda; Masako Kuno; Tomoko Kamiyama; Kyo Kozaki; Nobuhiko Nomura; Hiroyuki Egawa; Shinzaburo Minami; Kimiyasu Shiraki
Journal:  Antivir Chem Chemother       Date:  2003-09
View more
  62 in total

1.  Combination Therapy With Neuraminidase and Polymerase Inhibitors in Nude Mice Infected With Influenza Virus.

Authors:  Maki Kiso; Tiago J S Lopes; Seiya Yamayoshi; Mutsumi Ito; Makoto Yamashita; Noriko Nakajima; Hideki Hasegawa; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Infect Dis       Date:  2018-03-05       Impact factor: 5.226

Review 2.  Backs against the wall: novel and existing strategies used during the 2014-2015 Ebola virus outbreak.

Authors:  Gary Wong; Gary P Kobinger
Journal:  Clin Microbiol Rev       Date:  2015-07       Impact factor: 26.132

Review 3.  Crucial role of PA in virus life cycle and host adaptation of influenza A virus.

Authors:  Jiao Hu; Xiufan Liu
Journal:  Med Microbiol Immunol       Date:  2014-07-29       Impact factor: 3.402

4.  AZT acts as an anti-influenza nucleotide triphosphate targeting the catalytic site of A/PR/8/34/H1N1 RNA dependent RNA polymerase.

Authors:  Nataraj Sekhar Pagadala
Journal:  J Comput Aided Mol Des       Date:  2019-02-09       Impact factor: 3.686

5.  Extinction of West Nile Virus by Favipiravir through Lethal Mutagenesis.

Authors:  Estela Escribano-Romero; Nereida Jiménez de Oya; Esteban Domingo; Juan Carlos Saiz
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

6.  Synergistic lethal mutagenesis of hepatitis C virus.

Authors:  Isabel Gallego; María Eugenia Soria; Josep Gregori; Ana I de Ávila; Carlos García-Crespo; Elena Moreno; Ignacio Gadea; Jaime Esteban; Ricardo Fernández-Roblas; Juan Ignacio Esteban; Jordi Gómez; Josep Quer; Esteban Domingo; Celia Perales
Journal:  Antimicrob Agents Chemother       Date:  2019-09-30       Impact factor: 5.191

7.  Alterations in favipiravir (T-705) pharmacokinetics and biodistribution in a hamster model of viral hemorrhagic fever.

Authors:  Brian B Gowen; Eric J Sefing; Jonna B Westover; Donald F Smee; Joseph Hagloch; Yousuke Furuta; Jeffery O Hall
Journal:  Antiviral Res       Date:  2015-07-14       Impact factor: 5.970

8.  Distinct Effects of T-705 (Favipiravir) and Ribavirin on Influenza Virus Replication and Viral RNA Synthesis.

Authors:  Evelien Vanderlinden; Bram Vrancken; Jeroen Van Houdt; Vivek K Rajwanshi; Sarah Gillemot; Graciela Andrei; Philippe Lemey; Lieve Naesens
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Lack of mutational hot spots during decitabine-mediated HIV-1 mutagenesis.

Authors:  Jonathan M O Rawson; Sean R Landman; Cavan S Reilly; Laurent Bonnac; Steven E Patterson; Louis M Mansky
Journal:  Antimicrob Agents Chemother       Date:  2015-08-17       Impact factor: 5.191

10.  Antiviral Activity of Favipiravir (T-705) against a Broad Range of Paramyxoviruses In Vitro and against Human Metapneumovirus in Hamsters.

Authors:  D Jochmans; S van Nieuwkoop; S L Smits; J Neyts; R A M Fouchier; B G van den Hoogen
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.